Browsing Tag
JAK2 V617F
2 posts
Cogent Biosciences posts Q3 2025 results with $430m cash and pivotal trial momentum
Find out how Cogent Biosciences is using its $430 million cash runway and regulatory momentum to drive late-stage trials and pipeline expansion in 2025.
Vanda Pharmaceuticals’ VGT-1849A gets orphan drug designation for polycythemia vera treatment
Vanda Pharmaceuticals Inc. has achieved a critical regulatory milestone with the U.S. Food and Drug Administration (FDA) granting…